A new medication approved by the Food and Drug Administration (FDA) – the federal agency of the U.S. Department of Health and Human Services – promises to reduce 16 to 23 pounds in overweight individuals with weekly doses, according to a study conducted by the American Diabetes Association.
Entitled Tirzepatide and sold under the brand name Mounjaro, the medication was tested on obese and overweight individuals without diabetes, and the result was a reduction of 16 to 23.6 pounds.
According to endocrinologist and sports medicine specialist Gisele Lorenzoni, the dosages were responsible for each weight loss. “Patients who took 5 milligrams of Tirzepatide lost an average of 16 pounds; those who took a 10-milligram dose lost an average of 22 pounds, and those who took 15 milligrams lost 23.6 pounds,” the doctor highlights.
The study model used weekly injections in over 2,500 people without diabetes and with a BMI above 30 or 27, who had weight-related conditions such as high cholesterol, high blood pressure, and cardiovascular disease.
“This amount of weight loss of almost 24 pounds is very significant; it’s a number that for us is related to surgeries,” says the doctor.
Regarding side effects, the doctor mentions that common ones such as nausea, diarrhea, and constipation were reported. “It varies greatly from person to person, depending on the diet followed during treatment,” says Gisele.
The doctor warns that the medication is indicated for those who are overweight and suffer from obesity. “Obesity is a major health problem and should be treated as a chronic disease, associated with leading causes of death, such as heart disease, stroke, diabetes; thus, the release of this medication is very important for this audience,” emphasizes the endocrinologist.
These results are gratifying for us to continue our work in treating this audience by providing guidance and having effective mechanisms.
Participe da conversa